Alnylam Pharma (ALNY) Tops Q3 EPS by $3.06
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $236.22 +3.02%
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of $1.74, $3.06 better than the analyst estimate of ($1.32). Revenue for the quarter came in at $750.5 million versus the consensus estimate of $397.99 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- BofA maintains underperform ratings on six BDC stocks
- DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
